Advertisement
UK markets open in 5 hours 40 minutes

  • NIKKEI 225

    37,819.43
    -142.37 (-0.38%)
     

  • HANG SENG

    16,251.84
    0.00 (0.00%)
     

  • CRUDE OIL

    82.68
    -0.01 (-0.01%)
     

  • GOLD FUTURES

    2,385.70
    -2.70 (-0.11%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,300.34
    -1,832.99 (-3.58%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

Roche's emicizumab haemophilia drug succeeds in trial

Reuters - UK Focus

ZURICH, Dec (Shanghai: 600875.SS - news) 22 (Reuters) - Roche Holding AG (IOB: 0QOK.IL - news) 's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday.

"The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment," it said in a statement, adding all secondary endpoints were also met.

Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910, which represents a threat to more traditional treatments from Novo Nordisk (LSE: 0QIU.L - news) and Shire (Xetra: S7E.DE - news) . (Reporting by Michael Shields)